» Articles » PMID: 20233970

The Inherited Diseases of Hemoglobin Are an Emerging Global Health Burden

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2010 Mar 18
PMID 20233970
Citations 291
Authors
Affiliations
Soon will be listed here.
Abstract

It is estimated that in excess of 300,000 children are born each year with a severe inherited disorder of hemoglobin and that approximately 80% of these births occur in low- or middle-income countries. As these countries go through an epidemiologic transition, with a reduction in childhood and infant mortality due to improved public health measures, babies who would have previously died of these diseases before they were recognized are now surviving to present for diagnosis and treatment. Hence, they are presenting an increasing global health burden. Because of their uneven distribution in high-frequency populations, reflecting their complex population genetics, the true magnitude of this burden is still unknown. In many poor countries there are virtually no facilities for the diagnosis and management of these conditions, and even in richer countries there are limited data about their frequency, clinical course, or mortality. Without this information, it will be impossible to persuade governments about the increasing importance of these diseases. The situation will only be improved by concerted action on the part of the hematology community of the richer countries together with input from the major international health organizations and funding agencies.

Citing Articles

Prevalence of pulmonary dysfunction and its risk factors in patients with transfusion-dependent thalassaemia: protocol for a systematic review and meta-analysis.

Liang X, Lu Y, Huang Y, Pan L, Wu M, Lai Y BMJ Open. 2025; 15(2):e091847.

PMID: 39965944 PMC: 11836804. DOI: 10.1136/bmjopen-2024-091847.


Experience of Antenatal Thalassemia Screening and Prenatal Diagnosis from a Tertiary Care Teaching Hospital in Punjab.

Mashon R, Mandrelle K, Kakkar N Indian J Hematol Blood Transfus. 2025; 41(1):96-101.

PMID: 39917488 PMC: 11794726. DOI: 10.1007/s12288-024-01785-z.


Efficacy and safety of hydroxyurea therapy on patients with -thalassemia: a systematic review and meta-analysis.

Huang T, Jiang H, Tang G, Li J, Huang X, Huang Z Front Med (Lausanne). 2025; 11:1480831.

PMID: 39882530 PMC: 11774989. DOI: 10.3389/fmed.2024.1480831.


Haemoglobin (Hb) AE Bart's Disease in a Young Patient: A Case Report.

Adzahar S, Daud A, Syed Hassan S, Nordin M, Rameli N, Nizam Akbar N Cureus. 2025; 16(12):e76277.

PMID: 39845234 PMC: 11753891. DOI: 10.7759/cureus.76277.


Identification of small molecule agonists of fetal hemoglobin expression for the treatment of sickle cell disease.

Yang J, Toughiri R, Gounder A, Scheibe D, Petrus M, Fink S PLoS One. 2024; 19(11):e0307049.

PMID: 39504332 PMC: 11540224. DOI: 10.1371/journal.pone.0307049.


References
1.
De Silva S, Fisher C, Premawardhena A, Lamabadusuriya S, Peto T, Perera G . Thalassaemia in Sri Lanka: implications for the future health burden of Asian populations. Sri Lanka Thalassaemia Study Group. Lancet. 2000; 355(9206):786-91. DOI: 10.1016/s0140-6736(99)08246-x. View

2.
Weatherall D . Thalassemia as a global health problem: recent progress toward its control in the developing countries. Ann N Y Acad Sci. 2010; 1202:17-23. DOI: 10.1111/j.1749-6632.2010.05546.x. View

3.
Canali S, Corbellini G . Lessons from anti-thalassemia campaigns in Italy, before prenatal diagnosis. Med Secoli. 2003; 14(3):739-71. View

4.
Kulozik A, Wainscoat J, Serjeant G, KAR B, Essan G, Falusi A . Geographical survey of beta S-globin gene haplotypes: evidence for an independent Asian origin of the sickle-cell mutation. Am J Hum Genet. 1986; 39(2):239-44. PMC: 1683923. View

5.
KAR B, Satapathy R, Kulozik A, Kulozik M, Sirr S, Serjeant B . Sickle cell disease in Orissa State, India. Lancet. 1986; 2(8517):1198-201. DOI: 10.1016/s0140-6736(86)92205-1. View